<TABLE cellSpacing=0 cellPadding=0 width=600 align=center background=http://cancerconferences.com/HTML_email/Breast/breastcancer_0607/bg.gif border=0><TBODY><TR><TD>
</TD></TR><TR><TD vAlign=top><TABLE cellSpacing=0 cellPadding=2 width=580 align=center border=0><TBODY><TR><TD vAlign=top>
Chairs:
Carlos Arteaga, MD
Nashville, TN
Charles Geyer, Jr, MD, FACP
Pittsburgh, PA
<TABLE cellSpacing=0 cellPadding=0 width=575 align=center border=0><TBODY><TR><TD class=body1 vAlign=top width=70> </TD><TD class=body1 vAlign=top width=293>
Agenda</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Faculty
View Complete Faculty Details</TD></TR><TR><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70 bgColor=#f5f0d9>
6:00 pm</TD><TD class=body1 vAlign=top width=293 bgColor=#f5f0d9>
Registration and Reception
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
</TD></TR><TR><TD class=body1 vAlign=top width=70>
6:30 pm</TD><TD class=body1 vAlign=top width=293>
Welcome and Overview
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>
6:35 pm</TD><TD class=body1 vAlign=top width=293>
ErbB2 Structure, Signaling, Activation, and Inactivation in Breast Cancer: A 2007 Perspective
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Daniel Leahy, PhD
Baltimore, MD
</TD></TR><TR><TD class=body1 vAlign=top width=70>
6:50 pm</TD><TD class=body1 vAlign=top width=293>
Relationship Between ErbB and Hormone Receptor Signaling in Breast Cancer
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
C. Kent Osborne, MD
Houston, TX
</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>
7:05 pm</TD><TD class=body1 vAlign=top width=293>
Downstream Modulators of ErbB2 Activity: Implications for Predicting Response and Resistance to ErbB2-Directed Therapy
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Carlos Arteaga, MD
Nashville, TN
</TD></TR><TR><TD class=body1 vAlign=top width=70>
7:20 pm</TD><TD class=body1 vAlign=top width=293>
Tailoring Treatment Options for Patients With Relapsed or Newly Diagnosed ErbB2<SUP>+</SUP> Metastatic Breast Cancer
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Charles Geyer, Jr, MD, FACP
Pittsburgh, PA
</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>
7:40 pm</TD><TD class=body1 vAlign=top width=293>
Tailoring and Expanding the Role of ErbB2-Targeted Agents in Early-Stage Breast Cancer
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Edith Perez, MD
Jacksonville, FL
</TD></TR><TR><TD class=body1 vAlign=top width=70>
8:00 pm</TD><TD class=body1 vAlign=top width=293>
Implications of Targeting the Mammary Stem Cell: Data From Neoadjuvant Studies
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
Jenny Chang, MD
Houston, TX
</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>
8:20 pm</TD><TD class=body1 vAlign=top width=293>
Panel Discussion
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
</TD></TR><TR><TD class=body1 vAlign=top width=70>
8:30 pm</TD><TD class=body1 vAlign=top width=293>
Adjourn
</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>
</TD></TR></TBODY></TABLE>
<HR SIZE=1>
Program Overview
The
Tailoring ErbB-Directed Therapies for Optimized Care of Breast Cancer Patients symposium is designed to educate and update physicians on the latest ErbB2-targeted breast cancer treatments. Insights gained from studies of the structure and function of the ErbB receptor family, as well as their clinical implications, will be discussed. Two lectures will review current data regarding the treatment of early and advanced/metastatic ErbB2<SUP>+</SUP> breast cancer. In addition, important molecule pathways involved in the cross-talk of ErbB and hormone receptor signaling as well as downstream pathways that modulate ErbB function and contribute to resistance will be examined. Finally, the potential role of breast cancer stem cells in the natural history of the disease and the possibility of targeting this cell population with biologic agents will be discussed. Practical concerns such as patient selection and adverse event management will be considered along with the theoretical basis of ongoing trials and current hypotheses. The symposium will update oncologists on current treatments for ErbB2<SUP>+</SUP> breast cancer as well as strategies emerging from the laboratory and being translated into improvements in clinical care and patient selection.
This presentation was selected by the American Society of Clinical Oncology<SUP>®</SUP> as an independent educational activity held in conjunction with an ASCO<SUP>®</SUP> meeting. This presentation is not sponsored or endorsed by ASCO.
<HR SIZE=1>
Educational Objectives
At the conclusion of this meeting, you should be able to:
- <LI class=body1>Discuss how the structure of ErbB receptors impacts signaling mechanisms and the implications this has on the mechanism of action of targeted inhibitors <LI class=body1>Describe the interactions between the ErbB and estrogen receptor signaling pathways and review preclinical and clinical data evaluating combination regimens targeting both pathways <LI class=body1>Recognize potential mechanisms of resistance to ErbB2-targeted agents, including activation of alternate receptor signaling pathways such as insulin-like growth factor-1 receptor and Akt/mammalian target of rapamycin, inactivation of tumor suppressors, and ErbB2 receptor processing <LI class=body1>Evaluate recent clinical data from trials investigating the use of ErbB2-targeted agents in patients with previously untreated or relapsed/refractory metastatic breast cancer <LI class=body1>Review the efficacy and safety of ErbB2 inhibitors in the treatment of early-stage breast cancer as well as the rationale and schemas for next-generation adjuvant and neoadjuvant trials of ErbB2-targeted agents
- Explain the breast cancer stem cell theory and the potential role of biologic agents in targeting this cell population
<HR SIZE=1>
CME Accreditation
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 2
AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
<HR SIZE=1>
Venue
Hilton Chicago
International Ballroom North (Second Floor)
720 S. Michigan Ave.
Chicago, IL, 60605
Phone: (312) 922-4400
Fax: (312) 922-5240
<HR SIZE=1>
Registration
To view registration information please Click Here
If you are unable to access the above link, copy and paste the following link into the address bar of your broswer:
http://breastcancer.cancerconferences.com/registration.php
<HR SIZE=1>View More
For more information regarding this free CME meeting please Click Here
</TD></TR></TBODY></TABLE></TD></TR><TR><TD><TABLE cellSpacing=0 cellPadding=0 width=537 align=center border=0><TBODY><TR><TD>This activity is supported by an educational grant from GlaxoSmithKline Oncology.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
Linear Mode
